$146 Million is the total value of Foresite Capital Management III, LLC's 18 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 47.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $39,957,000 | +27.6% | 1,600,183 | +25.2% | 27.42% | +13.2% |
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $23,678,000 | +103.4% | 1,345,313 | +40.6% | 16.25% | +80.4% |
| WVE | Sell | WAVE Life Sciences Ltd. | $20,071,000 | +12.4% | 970,104 | -31.3% | 13.77% | -0.3% |
| NTLA | New | Intellia Therapeutics, Inc. | $16,305,000 | – | 763,688 | +100.0% | 11.19% | – |
| GBT | Buy | Global Blood Therapeutics, Inc. | $11,452,000 | +45.3% | 690,269 | +38.9% | 7.86% | +28.9% |
| ARDX | Sell | Ardelyx, Inc. | $5,251,000 | +4.2% | 601,485 | -7.2% | 3.60% | -7.6% |
| EPZM | Buy | Epizyme, Inc. | $5,241,000 | -9.3% | 511,777 | +7.3% | 3.60% | -19.6% |
| AVXS | Sell | Avexis, Inc. | $3,618,000 | -21.0% | 95,173 | -43.4% | 2.48% | -30.0% |
| Sell | NeuroDerm Ltd. | $3,274,000 | -20.7% | 201,469 | -31.1% | 2.25% | -29.6% | |
| ZFGN | Sell | Zafgen, Inc. | $3,220,000 | -54.1% | 537,495 | -48.9% | 2.21% | -59.3% |
| SYRS | New | Syros Pharmaceuticals, Inc. | $2,723,000 | – | 150,000 | +100.0% | 1.87% | – |
| BLCM | Bellicum Pharmaceuticals, Inc. | $2,670,000 | +38.6% | 205,990 | 0.0% | 1.83% | +23.0% | |
| AKTX | Sell | Akari Therapeutics, PLCsponsored adr | $2,659,000 | -28.0% | 197,072 | -25.3% | 1.82% | -36.2% |
| AIMT | Sell | Aimmune Therapeutics, Inc. | $2,543,000 | -47.2% | 235,020 | -33.8% | 1.74% | -53.2% |
| OREX | Sell | Orexigen Therapeutics, Inc. | $1,093,000 | -35.8% | 2,542,575 | -16.0% | 0.75% | -43.1% |
| LPCN | Sell | Lipocine Inc. | $920,000 | -77.2% | 302,640 | -23.8% | 0.63% | -79.8% |
| NSTG | New | NanoString Technologies, Inc. | $895,000 | – | 71,000 | +100.0% | 0.61% | – |
| BDSI | Sell | BioDelivery Sciences International, Inc. | $166,000 | -75.2% | 70,177 | -66.2% | 0.11% | -78.0% |
| IMGN | Exit | ImmunoGen, Inc. | $0 | – | -42,815 | -100.0% | -0.28% | – |
| EDIT | Exit | Editas Medicine, Inc. | $0 | – | -14,500 | -100.0% | -0.39% | – |
| DMTX | Exit | Dimension Therapeutics, Inc. | $0 | – | -98,297 | -100.0% | -0.60% | – |
| RGNX | Exit | Regenxbio Inc. | $0 | – | -100,000 | -100.0% | -0.84% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -94,403 | -100.0% | -1.93% | – |
| XENT | Exit | Intersect ENT, Inc. | $0 | – | -168,550 | -100.0% | -2.48% | – |
| SGMO | Exit | Sangamo Biosciences, Inc. | $0 | – | -544,816 | -100.0% | -2.55% | – |
| RGLS | Exit | Regulus Therapeutics Inc. | $0 | – | -789,091 | -100.0% | -4.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.